NEOVACS (ALNEV.PA) Stock Price, Forecast & Analysis
Europe - Euronext Paris - EPA:ALNEV - FR0014010856 - Common Stock
ALNEV.PA Key Statistics, Chart & Performance
The current stock price of ALNEV.PA is 0.0072 EUR. In the past month the price decreased by -36.84%. In the past year, price decreased by -100%.
ALNEV.PA Competitors/Peers
Symbol | Company Name | TA | FA | PE | Market Cap |
|---|---|---|---|---|---|
| 1AE.DE | ARGENX SE | 65.04 | 42.77B | ||
| ARGX.BR | ARGENX SE | 64.94 | 42.70B | ||
| 22UA.DE | BIONTECH SE-ADR | N/A | 20.72B | ||
| ABVX.PA | ABIVAX SA | N/A | 7.71B | ||
| 2X1.DE | ABIVAX SA | N/A | 7.64B | ||
| GXE.DE | GALAPAGOS NV | N/A | 1.88B | ||
| GLPG.AS | GALAPAGOS NV | N/A | 1.87B | ||
| 5CV.DE | CUREVAC NV | 6.71 | 876.36M | ||
| NANO.PA | NANOBIOTIX | N/A | 856.31M | ||
| IVA.PA | INVENTIVA SA | N/A | 782.22M | ||
| 6IV.DE | INVENTIVA SA | N/A | 753.57M | ||
| PHIL.MI | PHILOGEN SPA | 20 | 666.67M |
Related stock screener links
About ALNEV.PA
Company Profile
Neovacs SA is a biotechnology company focused on therapeutic vaccines targeting the treatment of autoimmune diseases. The company is headquartered in Suresnes, Ile-De-France and currently employs 16 full-time employees. The company went IPO on 2010-04-15. The company specializes in immunotherapy domain and providing treatment for autoimmune and inflammatory diseases. The firm researches and develops Kinoids, drug-candidates which aim to treat disease by including an antibody response in the patient. The firm focuses its development effort on two Kinoids for Crohn’s disease, Rheumatoid Arthritis and lupus disease. Neovacs SA’s portfolio of products includes TNF-Kinoids, IFN-Kinoids and VEGF-Kinoids. The firm operates in France and the United States. In May 2016, the Company signed a joint venture agreement with Stellar Biotechnologies Inc to create Neostell, owned by the Company in 70%.
Company Info
NEOVACS
14 Rue De La Republique
Suresnes ILE-DE-FRANCE FR
Employees: 22
Phone: 33153109300
NEOVACS / ALNEV.PA FAQ
What does ALNEV do?
Neovacs SA is a biotechnology company focused on therapeutic vaccines targeting the treatment of autoimmune diseases. The company is headquartered in Suresnes, Ile-De-France and currently employs 16 full-time employees. The company went IPO on 2010-04-15. The company specializes in immunotherapy domain and providing treatment for autoimmune and inflammatory diseases. The firm researches and develops Kinoids, drug-candidates which aim to treat disease by including an antibody response in the patient. The firm focuses its development effort on two Kinoids for Crohn’s disease, Rheumatoid Arthritis and lupus disease. Neovacs SA’s portfolio of products includes TNF-Kinoids, IFN-Kinoids and VEGF-Kinoids. The firm operates in France and the United States. In May 2016, the Company signed a joint venture agreement with Stellar Biotechnologies Inc to create Neostell, owned by the Company in 70%.
Can you provide the latest stock price for NEOVACS?
The current stock price of ALNEV.PA is 0.0072 EUR. The price decreased by -6.49% in the last trading session.
Does ALNEV stock pay dividends?
ALNEV.PA does not pay a dividend.
What is the ChartMill rating of NEOVACS stock?
ALNEV.PA has a ChartMill Technical rating of 0 out of 10 and a ChartMill Fundamental rating of 1 out of 10.
What is the Price/Earnings (PE) ratio of NEOVACS (ALNEV.PA)?
NEOVACS (ALNEV.PA) does not have a PE ratio as the earnings reported over the last twelve months were negative (-11314.18).
Is NEOVACS (ALNEV.PA) stock a good buy?
This depends on your investment goals. Check the Technical and Fundamental Analysis tabs for insights on ALNEV.PA.
What is the market capitalization of ALNEV stock?
NEOVACS (ALNEV.PA) has a market capitalization of 3.46K EUR. This makes ALNEV.PA a Nano Cap stock.
ALNEV.PA Technical Analysis
ALNEV.PA Fundamental Analysis
ChartMill assigns a fundamental rating of 1 / 10 to ALNEV.PA. ALNEV.PA has a bad profitability rating. Also its financial health evaluation is rather negative.
ALNEV.PA Financial Highlights
Over the last trailing twelve months ALNEV.PA reported a non-GAAP Earnings per Share(EPS) of -11314.18. The EPS increased by 99.99% compared to the year before.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| PM (TTM) | N/A | ||
| ROA | -18.89% | ||
| ROE | -23.07% | ||
| Debt/Equity | 0.01 |